Summary
EudraCT Number: 2009-016568-36
Sponsor's Protocol Code Number: EFC6204
National Competent Authority: Spain - AEMPS 
Clinical Trial Type: EEA CTA
Trial Status: Completed
Date on which this record was first entered in the EudraCT database: 2010-02-18
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016568-36/ES/

A. Protocol Information
A.1 Member State Concerned: Spain - AEMPS
A.2 EudraCT number: 2009-016568-36
A.3 Full title of the trial: Estudio aleatorizado, doble ciego y con triple simulación para comparar la eficacia de otamixabán con la de heparina no fraccionada más eptifibatida en pacientes con angina inestable/infarto de miocardio sin elevación del segmento ST y con estrategia invasiva temprana programada
__________________________________________________

Randomized, double-blind, triple-dummy trial to compare the efficacy of otamixaban with Unfractionated Heparin + eptifibatide, in patients with Unstable angina/Non ST segment Elevation Myocardial infarction scheduled to undergo an early invasive strategy
A.3.2 Name or abbreviated title of the trial where available: TAO
A.4.1 Sponsor's protocol code number: EFC6204
A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: sanofi-aventis recherche & développement
B.1.3.4	Country: France
B.3.1 and B.3.2	Status of the sponsor: Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support:
B.4.2 Country:
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: 
B.5.2 Functional name of contact point: 

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: No
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.2 Product code: XRP0673
D.3.4 Pharmaceutical form: Solution for injection
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Intravenous bolus use (Noncurrent)
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: otamixaban
D.3.9.1 CAS number: 219672-50-1
D.3.9.2 Current sponsor code: XRP0673
D.3.10 Strength
D.3.10.1 Concentration unit: mg/ml milligram(s)/millilitre
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 5 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 2
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: No
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.2 Product code: XRP0673
D.3.4 Pharmaceutical form: Solution for infusion
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Intravenous drip use (Noncurrent)
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: otamixaban
D.3.9.1 CAS number: 219672-50-1
D.3.9.2 Current sponsor code: XRP0673
D.3.10 Strength
D.3.10.1 Concentration unit: mg/ml milligram(s)/millilitre
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 5 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 3
D.1.2 and D.1.3 IMP Role: Comparator
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: INTEGRILIN 2 mg/ml, solución inyectable
D.2.1.1.2 Name of the Marketing Authorisation holder: GLAXO GROUP LTD.
D.2.1.2 Country which granted the Marketing Authorisation: Spain
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Solution for injection
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Intravenous bolus use (Noncurrent)
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: EPTIFIBATIDA
D.3.9.1 CAS number: 148031-34-9
D.3.9.3 Other descriptive name: EPTIFIBATIDE
D.3.10 Strength
D.3.10.1 Concentration unit: mg/ml milligram(s)/millilitre
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 2 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 4
D.1.2 and D.1.3 IMP Role: Comparator
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: INTEGRILIN 0,75 mg/ml, solución para perfusión
D.2.1.1.2 Name of the Marketing Authorisation holder: GLAXO GROUP LTD.
D.2.1.2 Country which granted the Marketing Authorisation: Spain
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Solution for infusion
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Intravenous drip use (Noncurrent)
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: EPTIFIBATIDA
D.3.9.1 CAS number: 148031-34-9
D.3.9.3 Other descriptive name: EPTIFIBATIDE
D.3.10 Strength
D.3.10.1 Concentration unit: mg/ml milligram(s)/millilitre
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 0.75 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 5
D.1.2 and D.1.3 IMP Role: Comparator
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: HEPARINE CHOAY 25 000 UI/5 ml
D.2.1.1.2 Name of the Marketing Authorisation holder: sanofi-aventis France
D.2.1.2 Country which granted the Marketing Authorisation: France
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: HEPARIN SODIUM
D.3.4 Pharmaceutical form: Concentrate for solution for injection
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Intravenous drip use (Noncurrent)
Intravenous bolus use (Noncurrent)
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: HEPARIN SODIUM
D.3.9.1 CAS number: 01/08/9041
D.3.10 Strength
D.3.10.1 Concentration unit: IU/ml international unit(s)/millilitre
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 5000 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: No
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Yes
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No

D.8 Information on Placebo
D.8 Placebo: 1
D.8.1 Is a Placebo used in this Trial? Yes
D.8.3 Pharmaceutical form of the placebo: Solution for injection
D.8.4 Route of administration of the placebo: Intravenous bolus use (Noncurrent)
D.8 Placebo: 2
D.8.1 Is a Placebo used in this Trial? Yes
D.8.3 Pharmaceutical form of the placebo: Solution for infusion
D.8.4 Route of administration of the placebo: Intravenous drip use (Noncurrent)
D.8 Placebo: 3
D.8.1 Is a Placebo used in this Trial? Yes
D.8.3 Pharmaceutical form of the placebo: Solution for injection
D.8.4 Route of administration of the placebo: Intravenous bolus use (Noncurrent)
D.8 Placebo: 4
D.8.1 Is a Placebo used in this Trial? Yes
D.8.3 Pharmaceutical form of the placebo: Solution for infusion
D.8.4 Route of administration of the placebo: Intravenous drip use (Noncurrent)
D.8 Placebo: 5
D.8.1 Is a Placebo used in this Trial? Yes
D.8.3 Pharmaceutical form of the placebo: Solution for injection
D.8.4 Route of administration of the placebo: Intravenous use

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: Síndrome coronario agudo con estrategia invasiva temprana programada
_______________________________________________

Acute coronary syndrome scheduled to undergo an early invasive strategy.
MedDRA Classification
E.1.2 Medical condition or disease under investigation:
E.1.2 Version: 12.1
E.1.2 Level: LLT
E.1.2 Classification code: 10051592
E.1.2 Term: Acute coronary syndrome
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: Demostrar la eficacia superior (compuesto de muertes por cualquier causa + infarto de miocardio) de otamixaban respecto a heparina no fracionada HNF + eptifibatida
_______________________________________________
To demonstrate the superior  efficacy (composite of all-cause death + Myocardial infarction) of otamixaban  to unfractionated heparin (UFH) + eptifibatide.
E.2.2 Secondary objectives of the trial: 1. demostrar la eficacia superior (compuesto de todas las muertes por cualquier causa + infarto de miocardio + cualquier ictus) del otamixaban respecto a HNF + eptifibatida.
2. documentar el efecto del otamixaban sobre la rehospitalización o la prolongación de la hospitalización por un nuevo episodio de isquemia miocárdica/infarto de miocardio comparado con HNF+ eptifibatida
3. documentar el efecto sobre la mortalidad (muerte por cualquier causa) del otamixaban comparado con HNF + eptifibatida.
4. documentar la seguridad del otamixaban comparado con HNF + eptifibatida 
5. documentar el efecto de otamixaban en las complicaciones trombóticas del procedimiento durante la ICP índice comparado con HNF +  eptifibatida.
E.2.3 Trial contains a sub-study: Yes
E.2.3.1 Full title, date and version of each sub-study and their related objectives: Análisis genómico

Se obtendrán muestras para análisis genómico en un sub-estudio. Este subestudio se describirá en un protocolo específico y estará sujeto a un informe de estudio a parte. Habrá un Consentimiento Informado específico disponible para este subestudio.
E.3 Principal inclusion criteria: Pacientes con síndrome coronario agudo sin elevación del segmento ST con los siguientes síntomas:

Síntomas isquémicos (dolor torácico o similar) en reposo &#8805; 10 minutos en las 24 horas anteriores a la aleatorización 
Y
uno de los dos criterios siguientes:
1. Nueva depresión del segmento ST &#8805; 0,1 mV (&#8805; 1 mm) o elevación transitoria del segmento ST (< 30 min) &#8805; 0,1 mV (&#8805; 1 mm) en al menos 2 derivaciones contiguas en el ECG, O 
2. Elevación de los biomarcadores cardiacos en las 24 horas anteriores a la aleatorización, definida como concentración elevada de troponina T, troponina I o CK-MB por encima del límite superior de normalidad
Y
Programado para una angiografía coronaria (seguido, si está indicado, de ICP) tan pronto como sea posible  (tras al menos 2 horas de tratamiento con medicación del estudio) y dentro de las 36 horas ( como muy tarde el día 3, si está justificado) 
Y
Obtención del consentimiento informado por escrito
E.4 Principal exclusion criteria: Cardiovasculares
E 06.	Procedimiento de revascularización ya realizado para el episodio en cuestión.
E 07.	Infarto agudo de miocardio con elevación del segmento ST 
7.3.1.3	Relacionados con tratamientos anteriores o concomitantes
E 08.	Paciente que haya recibido un tratamiento a dosis curativa con un anticoagulante (incluidos HNF, HBPM o bivalirudina) durante más de 24 horas antes de la aleatorización.
E 09.	Imposibilidad de interrumpir el tratamiento anticoagulante actual para cambiar a los productos en investigación conforme al calendario de transición especificado
E 10.	Pacientes que no pueden ser tratados con aspirina y clopidogrel (o cualquier otro agente antiplaquetario oral) según su ficha téctica. 
Criterios de exclusión relacionados con el comparador activo o el tratamiento basal obligatorio.
Relacionados con la eptifibatida
E 11.	Paciente que no puede ser tratado con eptifibatida conforme a la ficha técnica nacional (cuando esté disponible). En los países en que la eptifibatida no esté aprobada, se considerará la ficha técnica Europea o de EEUU
Relacionadas con la heparina no fraccionada
E 12.	Paciente que no puede ser tratado con heparina no fraccionada conforme a la ficha técnica nacional
Relacionadas con el otamixaban 
E 13.	Alergia al otamixaban
E.5 End points
E.5.1 Primary end point(s): Variable adjudicada compuesta por muerte por cualquier causa e infarto de miocardio (IM) nuevo desde la aleatorización (día 1) hasta el día 7.
Este criterio de evaluación se analizará desde la aleatorización  (día 1) hasta el día 30 como un análisis de sensibilidad.
E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: No
E.6.2 Prophylaxis: No
E.6.3 Therapy: Yes
E.6.4 Safety: Yes
E.6.5 Efficacy: Yes
E.6.6 Pharmacokinetic: Yes
E.6.7 Pharmacodynamic: No
E.6.8 Bioequivalence: No
E.6.9 Dose response: No
E.6.10 Pharmacogenetic: No
E.6.11 Pharmacogenomic: Yes
E.6.12 Pharmacoeconomic: Yes
E.6.13 Others: No
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: Information not present in EudraCT
E.7.1.2 Bioequivalence study: Information not present in EudraCT
E.7.1.3 Other: Information not present in EudraCT
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): No
E.7.3 Therapeutic confirmatory (Phase III): Yes
E.7.4 Therapeutic use (Phase IV): No
E.8 Design of the trial
E.8.1 Controlled: Yes
E.8.1.1 Randomised: Yes
E.8.1.2 Open: No
E.8.1.3 Single blind: No
E.8.1.4 Double blind: Yes
E.8.1.5 Parallel group: Yes
E.8.1.6 Cross over: No
E.8.1.7 Other: No
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): Yes
E.8.2.2 Placebo: No
E.8.2.3 Other: No
E.8.3 The trial involves single site in the Member State concerned: No
E.8.4 The trial involves multiple sites in the Member State concerned: Yes
E.8.4.1 Number of sites anticipated in Member State concerned: 23
E.8.5 The trial involves multiple Member States: Yes
E.8.5.1 Number of sites anticipated in the EEA: 223
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: Yes
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.6.3 If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned:
E.8.7 Trial has a data monitoring committee: Yes
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: 
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 2
E.8.9.1 In the Member State concerned months: 3
E.8.9.1 In the Member State concerned days: 0
E.8.9.2 In all countries concerned by the trial years: 2
E.8.9.2 In all countries concerned by the trial months: 3
E.8.9.2 In all countries concerned by the trial days: 0

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: No
F.1.1.1 In Utero: Information not present in EudraCT
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): Information not present in EudraCT
F.1.1.3 Newborns (0-27 days): Information not present in EudraCT
F.1.1.4 Infants and toddlers (28 days-23 months): Information not present in EudraCT
F.1.1.5 Children (2-11years): Information not present in EudraCT
F.1.1.6 Adolescents (12-17 years): Information not present in EudraCT
F.1.2 Adults (18-64 years): Yes
F.1.3 Elderly (>=65 years): Yes
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: Yes
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: Yes
F.3.3.1 Women of childbearing potential not using contraception  
(For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and
did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether
or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the
database on 2010-02-18) : Yes
F.3.3.2 Women of child-bearing potential using contraception: Yes
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: Yes
F.3.3.6 Subjects incapable of giving consent personally: No
F.3.3.7 Others: No
F.4 Planned number of subjects to be included
F.4.1 In the member state: 325
F.4.2 For a multinational trial
F.4.2.1 In the EEA: 3674
F.4.2.2 In the whole clinical trial: 10930

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2010-04-20
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2010-04-14

P. End of Trial
P. End of Trial Status: Completed
P. Date of the global end of the trial: 2013-05-07

